Skip to main content
. 2019 Jan 15;316(5):E749–E772. doi: 10.1152/ajpendo.00343.2018

Fig. 12.

Fig. 12.

Loss of nuclear matrix protein 4 (Nmp4) enhances therapeutically induced bone formation and femoral material properties. A and B: femoral (A) and L5 vetebral (B) bone volume per total volume (BV/TV) for all the experimental cohorts (age 17 wk) comparing WT and Nmp4−/− mice. We compared the therapies raloxifene (RAL), parathyroid hormone (PTH), and PTH + RAL to each other and to vehicle (VEH). Statistical analyses were performed using two-way ANOVA tests setting genotype and treatment as the independent variables. Statistical significance was set at P ≤ 0.05. There were a strong genotype effect and loss of Nmp4 enhanced femoral and L5 vertebral BV/TV over the cohorts. There was a strong treatment effect and PTH + RAL was the most efficacious osteoanabolic therapy for both femoral and L5 vertebral BV/TV. The analysis revealed a genotype × treatment interaction (G × T) denoted by an asterisk in the dot plot showing improved response in the PTH monotherapy and PTH + RAL combination therapy with loss of Nmp4. C and D: results of 3 point-bending analysis for ultimate stress (C) yield stress (D). There were strong genotype and treatment effects for both ultimate stress and yield stress. Data represent average ± SD; n = 8–15 mice/group.